PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Monopar Therapeutics Inc. (MNPR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS61023L1089
CUSIP61023L108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$62.29M
EPS (TTM)-$2.30
EBITDA (TTM)-$5.42M
Year Range$1.37 - $38.50
Target Price$18.00
Short %10.22%
Short Ratio0.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: MNPR vs. CALX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Monopar Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%200.00%400.00%600.00%800.00%MayJuneJulyAugustSeptemberOctober
391.16%
15.83%
MNPR (Monopar Therapeutics Inc.)
Benchmark (^GSPC)

Returns By Period

Monopar Therapeutics Inc. had a return of 853.53% year-to-date (YTD) and 702.48% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date853.53%22.29%
1 month139.44%1.65%
6 months391.21%15.83%
1 year702.48%39.98%
5 years (annualized)N/A13.99%
10 years (annualized)N/A11.23%

Monthly Returns

The table below presents the monthly returns of MNPR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-1.18%147.02%-17.95%-3.08%-7.42%19.48%-4.11%-31.71%182.01%853.53%
202351.05%-12.57%-55.59%-19.06%-13.07%-12.58%-13.33%-12.82%-4.02%-30.65%-32.56%17.24%-85.65%
2022-8.10%4.75%-17.48%-10.59%-6.14%7.48%-14.78%-8.16%-15.56%61.84%4.47%-7.78%-26.17%
202138.07%-13.61%-15.07%-3.06%-4.99%3.15%-9.85%-2.64%-5.80%-1.44%-8.29%-27.08%-47.55%
2020-13.55%-33.10%-25.36%2.72%4.62%-3.12%-1.61%-23.02%-5.26%-17.06%9.91%25.41%-63.13%
2019-37.36%-37.36%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of MNPR is 91, placing it in the top 9% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of MNPR is 9191
Combined Rank
The Sharpe Ratio Rank of MNPR is 6666Sharpe Ratio Rank
The Sortino Ratio Rank of MNPR is 9999Sortino Ratio Rank
The Omega Ratio Rank of MNPR is 9999Omega Ratio Rank
The Calmar Ratio Rank of MNPR is 9999Calmar Ratio Rank
The Martin Ratio Rank of MNPR is 9191Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


MNPR
Sharpe ratio
The chart of Sharpe ratio for MNPR, currently valued at 0.95, compared to the broader market-4.00-2.000.002.004.000.95
Sortino ratio
The chart of Sortino ratio for MNPR, currently valued at 8.00, compared to the broader market-4.00-2.000.002.004.006.008.00
Omega ratio
The chart of Omega ratio for MNPR, currently valued at 2.04, compared to the broader market0.501.001.502.002.04
Calmar ratio
The chart of Calmar ratio for MNPR, currently valued at 6.11, compared to the broader market0.002.004.006.006.11
Martin ratio
The chart of Martin ratio for MNPR, currently valued at 14.04, compared to the broader market-10.000.0010.0020.0030.0014.04
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 3.43, compared to the broader market-4.00-2.000.002.004.003.43
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 4.52, compared to the broader market-4.00-2.000.002.004.006.004.52
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.64, compared to the broader market0.501.001.502.001.64
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 3.17, compared to the broader market0.002.004.006.003.17
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 22.22, compared to the broader market-10.000.0010.0020.0030.0022.22

Sharpe Ratio

The current Monopar Therapeutics Inc. Sharpe ratio is 0.95. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Monopar Therapeutics Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00MayJuneJulyAugustSeptemberOctober
0.95
3.43
MNPR (Monopar Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

0

Monopar Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%MayJuneJulyAugustSeptemberOctober
-87.99%
-0.54%
MNPR (Monopar Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Monopar Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Monopar Therapeutics Inc. was 98.93%, occurring on Nov 20, 2023. The portfolio has not yet recovered.

The current Monopar Therapeutics Inc. drawdown is 87.99%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.93%Dec 23, 2019985Nov 20, 2023

Volatility

Volatility Chart

The current Monopar Therapeutics Inc. volatility is 213.90%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%MayJuneJulyAugustSeptemberOctober
213.90%
2.71%
MNPR (Monopar Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Monopar Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Monopar Therapeutics Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items